Metformin Use in Renal Impairment
Introduction to Metformin and Renal Function
- The American Diabetes Association recommends metformin as the first-line treatment for type 2 diabetes, but its use in patients with renal impairment requires careful consideration 1
- The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that metformin can be used safely in patients with mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²) with close monitoring and dose adjustment 1, 2
Recommendations Based on Renal Function
- For patients with an eGFR ≥45 mL/min/1.73 m², metformin can be used at the standard dose (up to 2550 mg/day) with annual renal function monitoring 1, 2
- For patients with an eGFR between 30-44 mL/min/1.73 m², the dose should be reduced to 1000 mg/day maximum, and renal function should be monitored every 3-6 months 1, 2
- For patients with an eGFR <30 mL/min/1.73 m², metformin is contraindicated due to the increased risk of lactic acidosis 1
Situations Requiring Temporary Discontinuation of Metformin
- Metformin should be discontinued during hospitalization, acute illness, or procedures that may compromise renal or hepatic function 2, 3, 4
- Metformin should be discontinued before procedures involving iodinated contrast media in patients with an eGFR between 30-60 mL/min/1.73 m² or those with a history of liver disease, alcoholism, or heart failure 4
Surveillance and Monitoring
- Renal function should be monitored annually in all patients taking metformin, and more frequently (every 3-6 months) in patients with an eGFR <60 mL/min/1.73 m² 1, 2
- Lactate levels should be monitored in fragile patients, and vitamin B12 levels should be monitored in long-term users 2, 4